(in thousands of Euros) Variation at current exchange rates. France 124, , % +0.9%

Transcription

1 2009 HALF-YEAR RESULTS 1. BOIRON GROUP SALES AS OF JUNE 30, 2009 (in thousands of Euros) France 124, , % +0.9% International : 90,604 95, % +7.9% Incl. Europe excluding France 73,470 75, % +8.0% Incl. North America 14,600 17, % +8.8% Incl. Other countries 2,534 2, % +0.2% Group Total 215, , % +3.9% (in thousands of Euros) Non-proprietary Homeopathic Medicines 129, , % -0.6% OTC Specialties 85,316 91, % +10.8% Other 0,627 0, % -23.3% Group Total 215, , % +3.9% 2. BOIRON GROUP RESULTS AS OF JUNE 30, 2009 (in thousands of Euros) 2008 (1) 2009 Variation Sales 215, , ,8% Operating income 19,206 21, ,4% Net Income - Group share 12,554 13, ,8% Cash Flow 27,946 24,395-12,7% Gross investments 9,003 14, ,4% Net cash position 45,866 50, ,6% (1) Operating income and net income for the year 2008 were impacted by respectively 97 thousand and 77 thousand according to the amendment of IAS 38 effective on 1st January Moreover, cash revenue and paid interests are now excluded from cash flows. Out of further deterioration in economic environment in the second half-year, the profitability of the group throughout the year should be close to that of The half-year report was published in line with the provisions of Article of the French Securities and Exchange Commission [AMF] Regulations. It is available on the Company s website: ( Our next update: October 23, 2009, at market close, publication of quarterly sales and financial information as of September 30, 2009, Person responsible for financial information: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA Find us at

2 2009 FIRST QUARTER ACTIVITY In thousands of Euros France 65,728 67, % +2.2% International : 51,152 55, % +12.2% Incl. Europe excluding France 41,346 45, % +15.9% Incl. North America 8,446 8, % -3.2% Incl. Other countries 1,360 1, % -2.8% Group Total 116, , % +6.6% In thousands of Euros Non-proprietary Homeopathic Medicines 67,052 66, % -0.9% OTC Specialties 49,468 55, % +16.9% Other 0,360 0, % -25.6% Group Total 116, , % +6.6% Next update: August , after the close of the stock market, publication of Half -Year financial information. Financial information manager: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA Find us at

3 2008 RESULTS At its meeting of March 11, 2009, the Board of Directors of BOIRON, chaired by Christian BOIRON, approved the company financial statements and the consolidated financial statements in respect of the 2008 fiscal year. It was decided to call an Combined Shareholders' Meeting for May 14, 2009 at the Company's headquarters in Sainte Foy les Lyon. CHANGE IN CONSOLIDATED RESULTS Consolidated data as of December Change (thousands of euros) 2008/2007 Sales 434, , % Operating income * 44,687 57, % Net income Group share 27,130 39, % Cash flow 61,117 81, % Net investment 18,459 24, % Net cash position 50,297 74, % * From 2008, the operating profitability indicator will be operating income, replacing the operating income used previously. The Board of Directors will recommend to the Combined Shareholders' Meeting the distribution of a dividend of 0.60 per share. The dividend will be paid out on June 5, Obviously, the global economic environment does not allow to give a trend for 2009 Group s performance. Next update: April 28th 2009, after the close of the stock market, publication of sales and quarterly information as of March 31, Financial information manager: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA Find us at

4 ACTIVITY IN 2008 QUARTERLY ACTIVITY IN 2008 (variation at rate, in thousands of euros) 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Var Var Var Var. France 66,087 65, % 59,687 59, % 62,562 65, % 75,859 74, % International : 42,472 51, % 33,210 39, % 42,579 49, % 51,838 61, % Incl. Europe excluding France 33,221 41, % 25,646 32, % 33,672 41, % 40,581 50, % Incl. North America 7,942 8, % 6,447 6, % 7,595 7, % 10,213 10, % Incl. Other countries 1,309 1, % 1,117 1, % 1,312 1, % 1,044 1, % Group Total 108, , % 92,897 98, % 105, , % 127, , % 1st Quarter 2nd Quarter 3rd Quarter 4th Quarter Var Var Var Var. Non-proprietary Homeopathic Medicines 68,331 67, % 63,195 62, % 59,117 56, % 71,654 72, % OTC Specialties 39,802 49, % 29,246 35, % 45,864 57, % 55,770 63, % Other % % % % Group Total 108, , % 92,897 98, % 105, , % 127, , % CUMULATIVE ACTIVITY AS OF THE END OF DECEMBER 2008 (in thousands of euros) 2007 Retraité France * 264, , % +0.2% International : 170, , % +19.6% Incl. Europe excluding France 133, , % +23.3% Incl. North America 32,197 32, % +8.0% Incl. Other countries * 4,782 4, % -2.9% Group Total 434, , % +7.8% Up to 2007, international sales (excluding Europe and North America) were registered as "France and others" amounting 268,977 thousand as of December 31, * 2008 Non-proprietary Homeopathic Medicines 273, , , % -1.2% OTC Specialties 173, , , % +21.8% Other -12,766 1,315 1, % -12.6% Group Total 434, , , % +7.8% In accordance with the new French commercial terms applicable in France (Chatel Act), service and coordination contracts, previously included in "Other", are now broken down by product lines. Data for the end of December 2007 were accordingly restated. Retrouvez-nous sur

5 KEY EVENTS DURING THE FOURTH QUARTER The information/consultation process carried out by the central works council concerning the regrouping of the activities of 5 laboratories with those of 8 others in France was completed on 27 November This reorganisation will be implemented in several stages: Activities at the Metz laboratory have been transferred to the Nancy laboratory and the two laboratories in Nantes have been merged. By the end of the first half of 2009, the activities at the Amiens laboratory will be split between several sites and the two laboratories in Bordeaux will be merged. The Tours and Orléans sites will be merged in AFEP-MEDEF RECOMMENDATIONS ON THE COMPENSATION OF EXECUTIVE CORPORATE OFFICERS At its meeting on 12 December 2008, the Boiron Board of Directors reviewed the recommendations issued jointly by AFEP and MEDEF on 6 October 2008 concerning the compensation paid to executive corporate officers, and confirmed that the company agrees with the basis of these recommendations, which are in accordance with its own code of ethics and practices. On 11 March Boiron will announce 2008 annual results, significantly improved compared to Next update: Mars 11 th 2009, after the close of the stock market, publication of results 2008 Financial information manager: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA Retrouvez-nous sur

6 ACTIVITY IN THE THIRD QUARTER OF 2008 CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2008 (in thousands of euros) 2007 Retraité France * 188, , % +1.0% International : 118, , % +19.4% Incl. Europe excluding France 92, , % +22.4% Incl. North America 21,984 22, % +10.6% Incl. Other countries * 3,738 3, % -3.6% Group Total 306, , % +8.1% * Up to 2007, international sales (excluding Europe and North America) were registered as "France and others" amounting 192,074 thousand as of September 30, * 2008 Non-proprietary Homeopathic Medicines 198, , , % -1.9% OTC Specialties 116, , , % +24.8% Other -8,819 1, % -11.4% Group Total 306, , , % +8.1% * In accordance with the new French commercial terms applicable in France (Chatel Act), service and coordination contracts, previously included in "Other", are now broken down by product lines. Data for the end of September 2007 were accordingly restated. DEVELOPMENT OF BUSINESS IN THE THIRD QUARTER (variation at rate, in thousands of euros) 1st Quarter 2nd Quarter 3rd Quarter Var Var Var. France 66,087 65, % 59,687 59, % 62,562 65, % International : 42,472 51, % 33,210 39, % 42,579 49, % Incl. Europe excluding France 33,221 41, % 25,646 32, % 33,672 41, % Incl. North America 7,942 8, % 6,447 6, % 7,595 7, % Incl. Other countries 1,309 1, % 1,117 1, % 1,312 1, % Group Total 108, , % 92,897 98, % 105, , % 1st Quarter 2nd Quarter 3rd Quarter Var Var Var. Non-proprietary Homeopathic Medicines 68,331 67, % 63,195 62, % 59,117 56, % OTC Specialties 39,802 49, % 29,246 35, % 45,864 57, % Other % % % Total Groupe % % % HIGHLIGHTS OF THIRD QUARTER On October 2, 2008, a project of grouping the activities of 5 regional laboratories with those of 8 others in France was presented to the central works council and is ly the subject of an information/consultation process. This project has been the subject of a financial press release published in October 3, 2008, available on the Company s website: For 2008, the Group confirms its expectation of a further growth in sales and results. Next update: January 27 th 2009, after the close of the stock market, publication of 2007 sales Financial information manager: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA Retrouvez-nous sur

7 2008 HALF-YEAR RESULTS 1. BOIRON GROUP SALES AS OF JUNE 30, 2008 (in thousands of Euros) 2007 Retraité France (1) 125, , , % -0.8% International : 75,682 75,682 90, % +20.7% Incl. Europe excluding France 58,867 58,867 73, % +23.5% Incl. North America 14,389 14,389 14, % +12.1% Incl. Other countries (1) 2,426 2,426 2, % +4.5% Group Total 201, , , % +7.3% 1. Up to 2007, international sales (excluding Europe and North America) were registered as "France and others" amounting 128,200 thousand as of June 30, (2) Non-proprietary Homeopathic Medicines 136, , , % -1.1% OTC Specialties 70,420 69,048 85, % +23.9% Other -5, % -29.9% Group Total 201, , , % +7.3% 2. In accordance with the new French commercial terms applicable in France (Chatel Act), service and coordination contracts, previously included in "Other", are now broken down by product lines. Data for the half-year of 2007 were accordingly restated. 2. BOIRON GROUP RESULTS AS OF JUNE 30, 2008 (in thousands of Euros) Variation Sales 201, , % Current operating income 8,714 18, % Net Income - Group share 5,452 12, % Cash Flow 19,660 28, % Gross investments 9,374 9, % Net cash position 38,820 45, % For fiscal year 2008, the Group confirms its expectation of further growth in sales and results. The half-year report was published in line with the provisions of Article of the French Securities and Exchange Commission [AMF] Regulations. It is in particular available on the Company s website: Our next update: October 24, 2008, at market close, publication of quarterly sales and financial information as of September 30, Person responsible for financial information: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA

8 2008 FIRST QUARTER ACTIVITY IFRS - In thousands of Euros France (1) 0,000 66,087 65, % -0.5% Europe excluding France 0,000 33,221 41, % +23.2% North America 0,000 7,942 8, % +16.1% Other countries (1) 0,000 1,309 1, % +3.9% Group Total 0, , , % +8.0% (1) Up to 2007, international sales (excluding Europe and North America) were registered as "France and others" amounting K 67,396 as at March 31st, IFRS - In thousands of Euros (2) 2008 Non-proprietary Homeopathic Medicines 71,190 68,331 67, % -1.5% OTC Specialties 40,481 39,802 49, % +24.5% Other -3, % -99.9% Group Total 108, , , % +8.0% (2) In accordance with new french commercial rules (loi Chatel), service and coordination contracts previously included in "Other" are now allocated to related product lines. First quarter 2007 data are adjusted. Boiron Group confirms its forecasts for year 2008 : sales increase and growth in operating income. Our next publication : September 1 st 2008 : 2008 Half -Year Activity Press Publication Financial Information Manager : Philippe MONTANT Contact for the Financial Information : Véronique BOUSCAYROL Investor Relations : +33 (0) actionnaires@boiron.fr Code ISIN : FR (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA Our website :

9 2007 RESULTS At its meeting of March 12, 2008, the Board of Directors of BOIRON, chaired by Christian BOIRON, approved the company financial statements and the consolidated financial statements in respect of the 2007 fiscal year. It was decided to call an Ordinary Shareholders' Meeting for May 15, 2008, at the Grand Hôtel Mercure Château Perrache in Lyon. CHANGE IN CONSOLIDATED RESULTS Consolidated data as of December 31 (thousands of euros) Change 2007/2006 Sales 398, , % Current operating income 26,599 43, % Restructuring costs (1) (8,512) - - Net income Group share 10,245 27, % Cash flow 37,334 62, % Net investment 16,095 18, % Net cash position 34,083 50, % (1) Restructuring costs stemming from the merger with Dolisos saw an improvement in operating income, which represented 10.1% of sales. Marketing expenses and research and development expenditure were up sharply, in line with the Group's strategic decisions. The Board of Directors will recommend to the Ordinary Shareholders' Meeting the distribution of a dividend of 0.55 euro per share. The dividend will be paid out on June 5, For Year 2008, the Group expects a new increase in sales and profitability. "For every PHYSICIAN in the world to integrate homeopathic medicines into daily practice." Next update: April 22, 2008: Publication in the media of sales and quarterly information as of March 31, Person responsible for financial information: Philippe MONTANT Financial information contact person: Véronique BOUSCAYROL Investor relations: +33 (0) actionnaires@boiron.fr ISIN code: FR (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA Find us at

10 ACTIVITY IN 2007 Fourth quarter In thousands of euros, IFRS Var. at rate France and others 74,914 76, % Europe excluding France 30,792 40, % North America 10,834 10, % Group Total 116, , % Cumulative activity as of the end of December 2007 In thousands of euros, IFRS Var. at rate Var. at fixed rate France and others 257, , % +4.6% Europe excluding France 109, , % +21.3% North America 32,040 32, % +7.8% Group Total 398, , % +9.5% In thousands of euros, IFRS Var. at rate Var. at fixed rate Non-proprietary Homeopathic Medicine 263, , % +4.0% OTC specialties 147, , % +18.9% Others* -12,208-12, % +4.7% Group Total 398, , % +9.5% * Including service and coordination contracts corresponding to services invoiced to Boiron by its customers and deducted from sales They are separated in order to better compare sales. In 2007, the Group saw its business grow by 8.9%: Growth in international sales reached 16.0%. International sales make up 41.1% of consolidated sales at rate (38.6% for 2006). Specialties now account for 40.0% of total sales, increasing by 18.1% (+8.6% in mainland France and +24.4% internationally). On 12 th of March, Boiron will announce 2007 annual results significantly improved and will specify his growth outlook for For every physician in the world to integrate homeopathic medicines into daily practice Next update: 12 March 2008, after the close of the stock market, publication of results for Financial information manager: Philippe MONTANT Investor relations: +33 (0) actionnaires@boiron.fr ISIN Code: FR (BOI) - Bloomberg: BOI FP - Reuters: BOIR.PA Visit our website at ww.boiron.com